摘要
目的观察利塞膦酸钠对绝经后骨质疏松症患者外周血单核细胞(PMBC)分泌肿瘤坏死因子(TNFα),白细胞介素1(IL1),白细胞介素6(IL6)水平及PBMC细胞数目的影响。方法采用双盲法将54名绝经后骨质疏松妇女随机分为治疗组和对照组,所有患者在用药前和用药后6月进行外周血单核细胞(PBMC)培养,并以放射免疫方法(RIA)检测培养上清中TNFα、IL1、IL6水平,计录PBMC细胞数目改变。结果利塞膦酸钠治疗组服药6月后,PBMC培养上清中TNFα、IL1水平较治疗前有所下降,IL6较前增加,与对照组无统计学差异,PBMC细胞数目也无明显改变(P>0.05)。结论利塞膦酸钠作为一种骨吸收抑制剂,口服治疗对PBMC分泌细胞因子(IL1、IL6和TNFα)及细胞数目并无明显影响,这些结果提示利塞膦酸钠并未通过影响PBMC参与骨代谢调节。
Objective To assess the influence on human peripheral blood mononuclear cells（PBMCs） after oral administration of residronate sodium for treatment of postmenopausal women with osteoporosis. Methods A randomized, double blind study was conducted among 54 postmenopausal women with osteoporosis, The concentration of cytokines （IL-1 ,IL-6,TNF-α） in PBMC culture medium were determined, and the amount of PBMC also analyzed before and 6 months after the administration of residronate sodium, Results No significant difference was found in cytokine concentration between residronate and placebo group 6 months after oral administration and the amount of PBMC （ P 〉 0.05 ）. Conclusions No evidence was shown in this study that residronate sodium takes part in bone metabolism by affecting PBMC.
出处
《中国骨质疏松杂志》
CAS
CSCD
2005年第4期512-514,共3页
Chinese Journal of Osteoporosis
